Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Alemtuzumab (Campath-1H) has been widely used for T-cell depletion following both conventional and reduced-intensity conditioning allografts. We studied the impact of alemtuzumab used in vivo and in vitro on infections, immune reconstitution, and allograft outcome. The use of alemtuzumab in vivo fol...
Auteurs principaux: | Chakrabarti, S, Hale, G, Waldmann, H |
---|---|
Format: | Journal article |
Langue: | English |
Publié: |
2004
|
Documents similaires
-
Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
par: Watson, C, et autres
Publié: (2004) -
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
par: Hale, G, et autres
Publié: (2002) -
The evolving role of alemtuzumab (Campath-1H) in renal transplantation
par: Phuong-Thu T Pham, et autres
Publié: (2008-12-01) -
T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
par: Hale, G, et autres
Publié: (1988) -
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
par: Clatworthy, MR, et autres
Publié: (2009)